Blog

Association between cholesterol, high-density lipoprotein, and glucose index and risks of cardiovascular and all-cause mortality in patients with calcific aortic valve stenosis: the ARISTOTLE cohort study | Cardiovascular Diabetology
Kanwar A, Thaden JJ, Nkomo VT. Management of patients with aortic valve stenosis. Mayo Clin Proc. 2018;93(4):488–508.

Article
PubMed

Google Scholar
Coffey S, Roberts-Thomson R, Brown A, Carapetis J, Chen M, Enriquez-Sarano M, Zühlke L, Prendergast BD. Global epidemiology of valvular heart disease. Nat Rev Cardiol. 2021;18(12):853–64.

Article
PubMed

Google Scholar
Chen QF, Shi S, Wang YF, Shi J, Liu C, Xu T, Ni C, Zhou X, Lin W, Peng Y, et al. Global, regional, and national burden of valvular heart disease, 1990 to 2021. J Am Heart Assoc. 2024;13(24): e037991.

Article
PubMed
PubMed Central

Google Scholar
Yadgir S, Johnson CO, Aboyans V, Adebayo OM, Adedoyin RA, Afarideh M, Alahdab F, Alashi A, Alipour V, Arabloo J, et al. Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990–2017. Circulation. 2020;141(21):1670–80.

Article
PubMed

Google Scholar
Benfari G, Essayagh B, Michelena HI, Ye Z, Inojosa JM, Ribichini FL, Crestanello J, Messika-Zeitoun D, Prendergast B, Wong BF, et al. Severe aortic stenosis: secular trends of incidence and outcomes. Eur Heart J. 2024;45(21):1877–86.

Article
PubMed

Google Scholar
Li SX, Patel NK, Flannery LD, Selberg A, Kandanelly RR, Morrison FJ, Kim J, Tanguturi VK, Crousillat DR, Shaqdan AW, et al. Trends in utilization of aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol. 2022;79(9):864–77.

Article
PubMed

Google Scholar
Coisne A, Lancellotti P, Habib G, Garbi M, Dahl JS, Barbanti M, Vannan MA, Vassiliou VS, Dudek D, Chioncel O, et al. ACC/AHA and ESC/EACTS guidelines for the management of valvular heart diseases: JACC guideline comparison. J Am Coll Cardiol. 2023;82(8):721–34.

Article
PubMed

Google Scholar
Wang A, Östgren CJ, Norhammar A, Kylhammar D, Jernberg T, Lind L, Söderberg S, Blomberg A, Engström G, Bergström G, et al. Aortic valve calcification across stages of dysglycemia in middle-aged individuals from the general population. Cardiovasc Diabetol. 2025;24(1):105.

Article
PubMed
PubMed Central

Google Scholar
Kopytek M, Ząbczyk M, Mazur P, Undas A, Natorska J. Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes. Cardiovasc Diabetol. 2020;19(1):92.

Article
PubMed
PubMed Central
CAS

Google Scholar
Lind V, Lundman P, Friberg L, Talbäck M, Hammar N, Walldius G, Ding M, Norhammar A. Dysglycaemia and incident aortic stenosis: a cohort study. Heart. 2025;111(14):671–7.

Article
PubMed
CAS

Google Scholar
Guo Z, Xiong Z, He L, Zhang S, Xu X, Chen G, Xie M, Zhang W, Hui Z, Li J, et al. Association between triglyceride-glucose-body mass index and risk of aortic stenosis progression in patients with non-severe aortic stenosis: a retrospective cohort study. Cardiovasc Diabetol. 2025;24(1):46.

Article
PubMed
PubMed Central
CAS

Google Scholar
Huang R, Xu X, Xu C, Zhang S, Xiong Z, Liu M, Huang Y, Wen H, Guo Y, Liao X, et al. Association between the insulin resistance and all-cause mortality in patients with moderate and severe aortic stenosis: a retrospective cohort study. Cardiovasc Diabetol. 2023;22(1):238.

Article
PubMed
PubMed Central
CAS

Google Scholar
Hou XZ, Lv YF, Li YS, Wu Q, Lv QY, Yang YT, Li LL, Ye XJ, Yang CY, Wang MS, et al. Association between different insulin resistance surrogates and all-cause mortality in patients with coronary heart disease and hypertension: NHANES longitudinal cohort study. Cardiovasc Diabetol. 2024;23(1):86.

Article
PubMed
PubMed Central
CAS

Google Scholar
Cai W, Xu J, Wu X, Chen Z, Zeng L, Song X, Zeng Y, Yu F. Association between triglyceride-glucose index and all-cause mortality in critically ill patients with ischemic stroke: analysis of the MIMIC-IV database. Cardiovasc Diabetol. 2023;22(1):138.

Article
PubMed
PubMed Central
CAS

Google Scholar
Liu X, Tan Z, Huang Y, Zhao H, Liu M, Yu P, Ma J, Zhao Y, Zhu W, Wang J. Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):124.

Article
PubMed
PubMed Central
CAS

Google Scholar
Shi W, Xing L, Jing L, Tian Y, Yan H, Sun Q, Dai D, Shi L, Liu S. Value of triglyceride-glucose index for the estimation of ischemic stroke risk: insights from a general population. Nutr Metab Cardiovasc Dis. 2020;30(2):245–53.

Article
PubMed
CAS

Google Scholar
Guo W, Zhu W, Wu J, Li X, Lu J, Qin P, Zhu C, Xu N, Zhang Q. Triglyceride glucose index is associated with arterial stiffness and 10-year cardiovascular disease risk in a Chinese population. Front Cardiovasc Med. 2021;8: 585776.

Article
PubMed
PubMed Central
CAS

Google Scholar
Su WY, Chen SC, Huang YT, Huang JC, Wu PY, Hsu WH, Lee MY. Comparison of the effects of fasting glucose, hemoglobin A(1c), and triglyceride-glucose index on cardiovascular events in type 2 diabetes mellitus. Nutrients. 2019. https://doi.org/10.3390/nu11112838.

Article
PubMed
PubMed Central

Google Scholar
Mansoori A, Nosrati M, Dorchin M, Mohammadyari F, Derakhshan-Nezhad E, Ferns G, Esmaily H, Ghayour-Mobarhan M. A novel index for diagnosis of type 2 diabetes mellitus: cholesterol, high density lipoprotein, and glucose (CHG) index. J Diabetes Investig. 2025;16(2):309–14.

Article
PubMed
CAS

Google Scholar
Mo D, Zhang P, Zhang M, Dai H, Guan J. Cholesterol, high-density lipoprotein, and glucose index versus triglyceride-glucose index in predicting cardiovascular disease risk: a cohort study. Cardiovasc Diabetol. 2025;24(1):116.

Article
PubMed
PubMed Central
CAS

Google Scholar
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561–632.

Article
PubMed

Google Scholar
Li F, Wang Y, Shi B, Sun S, Wang S, Pang S, Wu X. Association between the cumulative average triglyceride glucose-body mass index and cardiovascular disease incidence among the middle-aged and older population: a prospective nationwide cohort study in China. Cardiovasc Diabetol. 2024;23(1):16.

Article
PubMed
PubMed Central
CAS

Google Scholar
Shao Y, Hu H, Li Q, Cao C, Liu D, Han Y. Link between triglyceride-glucose-body mass index and future stroke risk in middle-aged and elderly Chinese: a nationwide prospective cohort study. Cardiovasc Diabetol. 2024;23(1):81.

Article
PubMed
PubMed Central
CAS

Google Scholar
Li H, Zuo Y, Qian F, Chen S, Tian X, Wang P, Li X, Guo X, Wu S, Wang A. Triglyceride-glucose index variability and incident cardiovascular disease: a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):105.

Article
PubMed
PubMed Central

Google Scholar
Ren Q, Huang Y, Liu Q, Chu T, Li G, Wu Z. Association between triglyceride glucose-waist height ratio index and cardiovascular disease in middle-aged and older Chinese individuals: a nationwide cohort study. Cardiovasc Diabetol. 2024;23(1):247.

Article
PubMed
PubMed Central
CAS

Google Scholar
Dang K, Wang X, Hu J, Zhang Y, Cheng L, Qi X, Liu L, Ming Z, Tao X, Li Y. The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease: NHANES 2003–2018. Cardiovasc Diabetol. 2024;23(1):8.

Article
PubMed
PubMed Central
CAS

Google Scholar
Wei X, Min Y, Song G, Ye X, Liu L. Association between triglyceride-glucose related indices with the all-cause and cause-specific mortality among the population with metabolic syndrome. Cardiovasc Diabetol. 2024;23(1):134.

Article
PubMed
PubMed Central
CAS

Google Scholar
Che B, Zhong C, Zhang R, Pu L, Zhao T, Zhang Y, Han L. Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data. Cardiovasc Diabetol. 2023;22(1):34.

Article
PubMed
PubMed Central
CAS

Google Scholar
Bortnick AE, Buzkova P, Otvos JD, Jensen MK, Tsai MY, Budoff MJ, Mackey RH, El Khoudary SR, Favari E, Kim RS, et al. High-density lipoprotein and long-term incidence and progression of aortic valve calcification: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2022;42(10):1272–82.

Article
PubMed
CAS

Google Scholar
Zieliński K, Kalińczuk Ł, Chmielak Z, Mintz GS, Dąbrowski M, Pręgowski J, Świerczewski M, Kowalik I, Demkow M, Hryniewiecki T, et al. Additive value of high-density lipoprotein cholesterol and C-reactive protein level assessment for prediction of 2-year mortality after transcatheter aortic valve implantation. Am J Cardiol. 2020;126:66–72.

Article
PubMed

Google Scholar
Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, Sowers JR. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119: 154766.

Article
PubMed
CAS

Google Scholar
Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293–302.

Article
PubMed
CAS

Google Scholar
Alizargar J, Bai CH, Hsieh NC, Wu SV. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol. 2020;19(1):8.

Article
PubMed
PubMed Central
CAS

Google Scholar
Ke Z, Huang R, Xu X, Liu W, Wang S, Zhang X, Guo Y, Zhuang X, Zhen L. Long-term high level of insulin resistance is associated with an increased prevalence of coronary artery calcification: the CARDIA study. J Am Heart Assoc. 2023;12(11): e028985.

Article
PubMed
PubMed Central
CAS

Google Scholar
Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol. 2019;234(6):8152–61.

Article
PubMed
CAS

Google Scholar
Takei Y, Tomiyama H, Tanaka N, Yamashina A, Chikamori T. Association between insulin resistance, oxidative stress, sympathetic activity and coronary microvascular function in patients with early stage impaired glucose metabolism. Circ J. 2022;86(5):866–73.

Article
PubMed
CAS

Google Scholar
Zhao J, Fan H, Wang T, Yu B, Mao S, Wang X, Zhang W, Wang L, Zhang Y, Ren Z, et al. TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients. Cardiovasc Diabetol. 2022;21(1):123.

Article
PubMed
PubMed Central

Google Scholar

Continue Reading

Tens of thousands return to shattered Gaza homes after ceasefire | Gaza News

Published On 11 Oct 2025

Tens of thousands of forcibly displaced Palestinians are making their way back to devastated areas in northern Gaza as Israeli forces stop operations as agreed under…

Continue Reading

PDLIM4 drives gastric cancer malignant progression and cisplatin resistance by inhibiting HSP70 ubiquitination and degradation via competitive interaction with STUB1 | Journal of Nanobiotechnology

The detailed methods of Cell Lines and Cell Culture, Quantitative Real-Time PCR (RT-qPCR), Cell proliferation, migration assay, Cell survival assay, Cell apoptosis analysis, Identification of Prognosis-Related Genes in Gastric Cancer, Drug Sensitivity Analysis, Stability assay, Cellular Uptake, In vitro Transfection Efficiency are described in Supplementary Experimental Procedures.

Tissue specimens

A total of 40 pairs of fresh GC tissues and adjacent normal tissues were obtained under the supervision of gastroenterologists. These samples were maintained at − 80 °C to be used in subsequent RT-qPCR and Western blotting analyses, or fixed in 10% formalin and embedded in paraffin for immunohistochemistry (IHC). Additionally, The Pathology Department at the First Affiliated Hospital of Nanchang University provided 210 paraffin-embedded GC tissue samples. All the samples originated from patients diagnosed with GC who underwent surgical procedures between January 2017 and January 2019, none of whom had received any prior treatment. The Ethics Committee of the First Affiliated Hospital of Nanchang University approved the study, and all participants provided informed consent (Approval Number: (2025) CDYFYYLK (04–030)).

siRNA, shRNA, plasmid construction, and cell transfection

General Biol (Anhui) Co., Ltd (Anhui, China) synthesized the siRNA and shRNA primers, with their sequences listed in Table S1. A segment of SFB, whose sequence is also listed in Table S1, was fused to the N-terminus of PDLIM4 to facilitate binding with S-Protein Agarose and Flag antibody. This construct was inserted into the PCDH-CMV-MCS-EF1-copGFP-T2A-Puro vector, resulting in the SFB-PDLIM4 construct. Variants of SFB-PDLIM4, including SFB-PDLIM4 (330AA), SFB-PDLIM4 (1-88AA), SFB-PDLIM4 (1-260AA), SFB-PDLIM4 (80-260AA), SFB-PDLIM4 (80-330AA), and SFB-PDLIM4 (250-330AA) were procured from PPL (Public Protein/Plasmid Library, China). The HSP70 variants, HSP70-ΔN, HSP70-ΔC, and HSP70-ΔABD were procured from LuoRui Biotech (Jiangsu, China). For siRNA and plasmid transfections, Lipo3000 (Thermo Fisher Scientific, USA) and jet PRIME® (Polyplus, France) were employed, respectively. To generate stable cell lines with either knockdown or overexpression of PDLIM4, we utilized psPAX2, pMD2.G, and the target plasmid for lentiviral packaging. The resulting viral supernatant was then used to infect MKN45 and HGC27 cells.

Western blotting

Total Proteins were split by SDS-PAGE, afterwards shifted to 0.45 μm nitrocellulose membranes (Millipore, USA). The membranes were incubated overnight with the primary antibody following 2 h block using 5% milk. Membranes were exposed to a secondary antibody the next day. Image acquisition was conducted using the UVP/ChemStudio Imaging System (Analytik Jena AG, Germany). The antibodies used included PDLIM4 (Abcam, Cat# ab251701), HSP70 (Proteintech, Cat# 10995–1-AP), STUB1 (Abmart, Cat# PHM9480), β-actin (ABclonal, Cat# AC026), GAPDH (Proteintech, Cat# 81640–5-RR), MYC (Proteintech, Cat# 16286–1-AP), Ub (Proteintech, Cat# 10201– 2-AP), HA (ABclonal, Cat# AE008), HA (Proteintech, Cat# 51064–2-AP), DYKDDDDK (Proteintech, Cat# 20543–1-AP), DYKDDDDK (Proteintech, Cat# 66008–4-Ig), P21 (ABclonal, Cat# A19094), P27 (ABclonal, Cat# A19095), bcl2 (Servicebio, Cat# GB154380), Bax (Servicebio, Cat# GB11690), E-cadherin (Proteintech, Cat# 20874–1-AP), MMP2 (Wanleibio, Cat# WL03224), MMP3 (Proteintech, Cat# 66338–1-Ig), MMP9 (Huabio, Cat# ET174-69), Vimentin (Huabio, Cat# ET1610-39), ERK (Proteintech, Cat# 11257–1-AP), P38 (Proteintech, Cat# 66234–1-Ig), JNK (Proteintech, Cat# 66210–1-Ig), p-ERK (Cohesion, Cat# CQA8093), p-P38 (Proteintech, Cat# 28796–1-AP), p-JNK1/2/3 (Cohesion, Cat# CQA8172), Integrin Alpha V + Beta3 (absin, Cat# abs122318), Integrin Alpha V + Beta3 (LMAI, Cat# LM-1310R), Rabbit IgG (Proteintech, Cat# 30000–0-AP) and Mouse IgG (Proteintech, Cat# B900620).

Immunohistochemistry (IHC)

The paraffin-embedded sections underwent deparaffinization and rehydration, antigen retrieval was performed with EDTA (pH 9.0). Subsequently, they were immersed in a 3% hydrogen peroxide solution for 15 min. Sections were incubated overnight at 4 °C with primary antibodies after 2 h block with 5% milk, including PDLIM4 (Abmart, Cat# PC6093M), HSP70 (Proteintech, Cat# 10995–1-AP), and Ki67 (Huabio, Cat# HA721115). The next day, the sections were treated with a secondary antibody for 1 h, then stained with DAB and counterstained with hematoxylin. A scoring system was employed to evaluate the degree of staining, assessing the proportion of positive cells using the following scale: 0 (0%), 1 (1–24% positive cells), 2 (25–49% positive cells), 3 (50–74% positive cells), and 4 (≥ 75% positive cells). The intensity of staining was rated as 0 for negative, 1 for weak, 2 for moderate, and 3 for strong. The immune reactivity score was obtained by multiplying the degree score with the intensity score, with the median value used to differentiate between low and high expression.

Immunofluorescence (IF)

MKN45 and HGC27 cells, transfected with SFB-PDLIM4 and HSP70-HA, were fixed using 4% paraformaldehyde for a duration of 30 min. Following this, 0.2% Triton X-100 was used to permeabilize the cells for 15 min. Following permeabilization, the cells were blocked with 5% goat serum for 1 h. Primary antibodies were used to incubate the cells overnight at 4 °C, and the next day, secondary antibodies were applied for 1 h. Imaging was conducted utilizing a ZEISS confocal laser scanning microscope (Germany).

Co-immunoprecipitation

The designated plasmids were used to transfect the cells, which were then lysed using IP lysis buffer (Servicebio, China) containing 50 × Cocktail (Servicebio, China). The cell lysates underwent incubation at 4 °C overnight for co-immunoprecipitation using specified antibody in conjunction with S-Protein Agarose (Millipore, USA) or Protein A/G Plus Sepharose 4FF Affinity Chromatography Resin (Sangon Biotech, China). The beads were washed with TBS buffer at least five times the next day. The final products were boiled in 2 × SDS-PAGE loading buffer (Solarbio, China) at 100 °C for 10 min. The immunoprecipitated samples were analyzed via western blotting.

Proximity ligation assay (PLA)

The PLA was performed using a NaveniFlex Cell Red kit (Navinci, Sweden). On the first day, gastric cancer cells were seeded onto slides, and on the second day, they were fixed and permeabilized. After blocking non-specific binding with Naveni Block, the samples were incubated overnight with primary antibodies (rabbit anti-PDLIM4 and mouse anti-HSP70 (Proteintech, Cat#66183–1-Ig) or mouse anti-IgG). Navenibody were applied and incubated after 1 × TBST washing, with subsequent ligation and amplification steps. Finally, we cleaned the slides and performed nuclear staining using DAPI (Beyotime, China), and took photos using a ZEISS confocal laser scanning microscope (Germany).

Mouse xenograft model

The animal research received approval from the Ethics Committee of the First Affiliated Hospital of Nanchang University (Ethics Number: CDYFY-IACUC-202309QR019). Hangzhou Ziyuan Laboratory Animal Technology Co., Ltd. supplied female BALB/c nude mice that were four weeks old. For the mouse xenograft tumor assay, nude mice received a subcutaneous injection of about 5 million cells, and the tumor volume was measured every three days. The calculated using the formula: volume = length × width^2 × 0.5. The mice were euthanized when the tumors grew to a size of 15 mm in diameter, and the tumors were either embedded in paraffin or kept at −80 °C.

Synthesis of siPDLIM4 LNPs, DDP LNPs and siPDLIM4/DDP LNPs

Lipid nanoparticles (LNPs) were created by dissolving MC3, DSPC, DMG-PEG2000, cholesterol, and DSPE-PEG-RGD in ethanol with a molar ratio of 50:10:1.5:38.5:1. Subsequently, the lipid mixture and siRNA were combined at a nitrogen-to-phosphate (N/P) ratio of 6, which prepare LNPs encapsulating siPDLIM4 or/and DDP using a microfluidic cartridge.

Characterization of lipid nanoparticles

The size and zeta potential of the nanoparticles were measured using the Zetasizer Nano ZS90 (Malvern Instruments, UK). Transmission electron microscopy (TEM, Japan) was utilized to analyze the nanoparticles’ morphological characteristics. The encapsulation efficiency of siPDLIM4 was assessed using ultraviolet–visible spectroscopy (UV–Vis), while the encapsulation efficiency of DDP was assessed using inductively coupled plasma optical emission spectrometry (ICP-OES). Firstly, we used ICP-OES: Agilent 5110 to detect the Pt content, which is converted to 1 μg/ml Pt≈1.538 μg/ml DDP. We diluted the siPDIM4/DDP LNPs 50 times and measured the average concentration of Pt is 3.786 mg/l, so the Pt concentration in the siPDIM4/DDP LNPs is 189.3 mg/l, which is equivalent to DDP concentration of 291.16 mg/l. We synthesized the siPDIM4/DDP LNPs a total of 10 ml, therefore the content of DDP is 2.9116 mg. 5 mg DDP were used in our synthetic material, the encapsulation efficiency of DDP is 2.9116 mg/5 mg = 58.23%. The concentration of the siPDIM4/DDP LNPs is 3 mg/ml and the volume is 10 ml, therefore, the DDP loading capacity = encapsulated DDP mass/encapsulated DDP mass + carrier mass (2.9116 mg/2.9116 mg + 30 mg = 8.85%).

Cisplatin release profile from LNPs

We conducted a drug release curve in PH6.0 PBS, which is a tumor-mimicking environments. We used the siPDIM4/DDP LNPs with a volume of 1 ml and a concentration of 3 mg/ml for drug release. Then we put it into a dialysis bag, the dialysis solution was 30 ml PBS buffer with pH 6.0. Later, we took out 1 ml dialysis solution at regular intervals and measured the content of Pt released by ICP-OES: Agilent 5110, and converted it to DDP content. The cumulative release = release DDP amount/total DDP amount.

Pharmacokinetic assay and biodistribution of SIPDIM4/DDP LNPS in mice

Healthy female mice were assigned into 3 groups randomly (n = 3), with every group receiving a tail vein injection of either naked siPDLIM4, or siPDLIM4 LNPs, siPDLIM4/DDP LNPs, each at a dose of 1 nmol siRNA. The orbital vein was used to collect blood samples using heparinized tubes at predetermined intervals. The fluorescence intensity of CY5-labeled siPDLIM4 in the blood was calculated using a microplate reader to assess pharmacokinetics. For the biodistribution study, healthy female BALB/c nude mice with subcutaneous tumors were randomly divided into two groups (n = 16), with each group receiving an intravenous injection of either naked Cy5-siPDLIM4 or Cy5-siPDLIM4/DDP LNPs. After 1, 6, 24 h, the fluorescence intensity of CY5-siPDLIM4 in major organs and tumors was measured using the small animal CT/live imaging all-in-one machine (Milabs B.V.).

Anti-tumor efficacy and toxicity of siPDLIM4 LNPs, DDP LNPs and siPDLIM4/DDP LNPs

In the mouse xenograft tumor assay, nude mice received subcutaneous injections of approximately 5 million MKN45 cells. Then, on the sixth day the mice of xenograft tumors were divided into five groups (n = 6) through random allocation. On the seventh day, the mice received injections via the tail vein (This injection method refers to relevant literatures [26, 29, 30, 33, 34]) with either PBS, LNPs, siPDLIM4 LNPs, DDP LNPs, or siPDLIM4/DDP LNPs with 1 nmol siRNA or/and DDP dosage of 2 mg/kg, administered every three days for a total of six cycles, which primarily informed by existing literatures [35,36,37]. On the 25th day, the mice were executed, and their major organs and tumors were harvested and preserved in 4% paraformaldehyde for IHC and HE staining. Servicebio (Wuhan, China) conducted an analysis of blood biochemical parameters such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea, and creatinine (Crea).

Data sources

The Cancer Genome Atlas (TCGA) database (http://cancergenome.nih.gov/) provided us with clinical information and RNA-seq transcriptomic data on GC. Additionally, four datasets—GSE66229, GSE122401, GSE179252, and GSE184336 were derived from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/). The GDSC2 drug sensitivity data were accessed from the Genomics of Drug Sensitivity in Cancer (GDSC) database via GitHub (https://github.com/maese005/oncoPredict/tree/main/vignettes). Samples lacking complete clinical information were deemed ineligible and subsequently excluded from the study. Following the preprocessing of raw data, which encompassed sample deduplication, data normalization, probe annotation, gene filtering, and clinical grouping. To analyze differential gene expression between tumor and normal tissues, we used the Lima package in R.

Statistical analysis

We used R and GraphPad Prism 9.0 for performing statistical analyses. Results are displayed as the mean ± standard deviation based on three different experiments. For differences between two groups, a t-test was utilized, whereas two-way or one-way ANOVA was employed for comparisons among multiple groups. Spearman’s rank order correlation was used to perform the correlation analysis. A P-value below 0.05 was regarded as a sign of statistical significance.

Blog

Association between cholesterol, high-density lipoprotein, and glucose index and risks of cardiovascular and all-cause mortality in patients with calcific aortic valve stenosis: the ARISTOTLE cohort study | Cardiovascular Diabetology

Continue Reading

Pakistan achieves first successful corneal transplant from female donor

Continue Reading

Tens of thousands return to shattered Gaza homes after ceasefire | Gaza News

Continue Reading

DPM discusses ME situation with FMs of Egypt, Azerbaijan – RADIO PAKISTAN

Continue Reading

Space News: What are solar storms and the solar wind? 3 astrophysicists explain how particles coming from the Sun interact with Earth – Lake County News,California

Continue Reading

Samsung’s Next Flagship Phones Could Run on the World’s First 2nm Chip

Continue Reading

Recap: France 3-0 Azerbaijan; UEFA World Cup Qualifiers 2026

Continue Reading

Salman Khan Calls Neelam Giri A Weak Competitor; Says ‘Saach Karwa Hota Hain…’

Continue Reading

Timex Just Brought Back Its Coolest ’70s Digital Watch (and It’s Only £155)

Continue Reading

PDLIM4 drives gastric cancer malignant progression and cisplatin resistance by inhibiting HSP70 ubiquitination and degradation via competitive interaction with STUB1 | Journal of Nanobiotechnology

Tissue specimens

siRNA, shRNA, plasmid construction, and cell transfection

Western blotting

Immunohistochemistry (IHC)

Immunofluorescence (IF)

Co-immunoprecipitation

Proximity ligation assay (PLA)

Mouse xenograft model

Synthesis of siPDLIM4 LNPs, DDP LNPs and siPDLIM4/DDP LNPs

Characterization of lipid nanoparticles

Cisplatin release profile from LNPs

Pharmacokinetic assay and biodistribution of SIPDIM4/DDP LNPS in mice

Anti-tumor efficacy and toxicity of siPDLIM4 LNPs, DDP LNPs and siPDLIM4/DDP LNPs

Data sources

Statistical analysis

Continue Reading